Pre-IPO Deshengtang Pharmaceutical - Benign Development Momentum, but Still Face Some Risks
Deshengtang has hope for an early turnaround if benign development momentum could continue. But its business model does not have a high moat, so...
500 Views
Hong Kong Connect Flows (Jun 9th): Tencent, China Mobile, CCB
We analyzed the Hong Kong Connect Scheme for last week and highlight flows for Tencent, China Mobile, and China Construction Bank.
514 Views
China Healthcare Weekly (March.3) - TCM New Policy, Pfizer to Acquire Seagen, Haohai Biological
New favorable policy for TCM industry was released. We analyzed our top picks. Pfizer is in talks to acquire Seagen, but we're conservative about...
714 Views
Hong Kong Connect Flows (Feb 3rd): Meituan, Sensetime, Tencent, CCB, HKEx
We analyzed southbound Hong Kong connect flows in the past week and highlight flows for Meituan, Sensetime, Tencent, China Construction Bank, Hong...
460 Views
Hong Kong CEO & Director Dealings (20 Jan): Asymchem Labs, Honbridge, Flat Glass, Gushengtang
The data in this insight is collated from the "shareholding disclosure" link on the HKEx website. These insights also flag those companies where...
627 Views